drugset / Trial / NCT00567346

Efficacy and Safety of Grass Pollen Sublingual Immunotherapy

NCT00567346 ↗

Phase 2/3 Completed 605 enrolled Artu Biologicals
RandomizedParallel-groupTriple-blindTreatment

Summary

The study is assessing efficacy and safety of three different dosage regimens of grass pollen sublingual immunotherapy in adult patients suffering from grass pollen related rhinoconjunctivitis.

Timeline

Start
2006-12
Primary completion
2007-10
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oralgen Vaccine 9500 unknown Other
Comparator Oralgen Vaccine 19000 unknown Other

Indications